Physician profile
Paul S Schulz
NPI 1649260993
$189,377.10
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $37K · 2021: $22K · 2022: $21K · 2023: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $4,194 · Consulting Fee: $2,080 · Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,600.00 |
| Travel and Lodging | $4,194.36 |
| Consulting Fee | $2,080.00 |
| Food and Beverage | $1,528.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $98,185.85 | 2019-2023 | Descovy, Biktarvy, Sunlenca |
| Merck Sharp & Dohme LLC | $87,709.14 | 2019-2023 | Vaxneuvance, Recarbrio, Zerbaxa |
| Theratechnologies INC. | $1,664.27 | 2019-2022 | |
| Abbott Laboratories | $466.17 | 2022 | |
| Mayne Pharma Commercial LLC | $213.80 | 2019-2022 | |
| Astellas Pharma US INC | $154.72 | 2019-2020 | |
| Viiv Healthcare Company | $127.25 | 2019-2022 | |
| Shionogi INC | $120.54 | 2022-2023 | Fetroja |
| Melinta Therapeutics, LLC | $114.89 | 2019 | |
| Allergan, INC. | $113.53 | 2019-2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Janssen Biotech, INC. | $99.10 | 2019-2023 | Symtuza |
| Pfizer INC. | $48.40 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $47.97 | 2019-2021 | |
| Insmed, INC. | $45.59 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $34.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Dynavax Technologies Corporation | $26.43 | 2019 | |
| Medline Industries LP | $20.07 | 2022 | |
| Emd Serono, INC. | $19.04 | 2019 | |
| Vyera Pharmaceuticals, LLC | $18.96 | 2019 | |
| Nabriva Therapeutics, Plc | $18.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schulz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.